DelveInsight’s “Friedreich’s Ataxia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Friedreich’s Ataxia market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Friedreich’s Ataxia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Friedreich’s Ataxia: An Overview
Friedreich’s Ataxia (FA) is a rare autosomal recessive neurodegenerative disease that causes progressive nervous system damage and movement problems. It usually begins in childhood and leads to impaired muscle coordination (ataxia) that worsens over time.
Most patients carry homozygous GAA expansions in the first intron of the frataxin gene on chromosome 9. Frataxin is a mitochondrial protein. Due to epigenetic alterations, frataxin expression is reduced significantly, and its deficiency leads to mitochondrial iron overload, defective energy supply, and generation of reactive oxygen species.
Friedreich’s Ataxia Market Key Facts
As per the statistics by the National Institute of Neurological Disorders and Stroke, although rare, Friedreich’s Ataxia is the most common form of hereditary ataxia in the United States, affecting about 1 in every 50,000 people.
In a study by Delatycki et al.(2020) the availability of molecular diagnosis, Friedreich’s Ataxia was estimated to affect about 1/50,000 people with an estimated carrier prevalence of about 1/110. However, recent studies based on molecular data suggest a higher prevalence.
Globally, few companies are developing therapies to provide a treatment option to patients suffering exclusively from Friedreich. Omaveloxolone (Reata Pharmaceuticals), RT001 (Retrotope), Vatiquinone (PTC Therapeutics), Leriglitazone (Minoryx Therapeutics), are the therapies that are currently under development and are expected to hit the market in the coming years.
Treatments for Friedreich’s Ataxia have targeted specific symptoms of the disease rather than the underlying cause, and to a greater degree, these therapeutic options still make up the gold standard for Friedreich’s Ataxia care. There is no cure for Friedreich’s Ataxia, but there are ways to manage the condition and improve the quality of life for those living with Friedreich’s Ataxia.
Friedreich’s Ataxia Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Friedreich’s Ataxia market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Friedreich’s Ataxia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Friedreich’s Ataxia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
The Report Covers the Friedreich’s Ataxia Epidemiology Segmentated by –
Total Prevalent Cases of Friedreich’s Ataxia
Total Prevalent Population of Friedreich’s Ataxia
Diagnosed and Treatable Population of Friedreich’s Ataxia
Prevalence of Friedreich’s Ataxia based on onset types
Friedreich’s Ataxia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Friedreich’s Ataxia market or expected to get launched during the study period. The analysis covers the Friedreich’s Ataxia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Friedreich’s Ataxia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Friedreich’s Ataxia Market Will Evolve by 2032 @ https://www.delveinsight.com/sample-request/friedreichs-ataxia-market
Some of the key companies in Friedreich’s Ataxia Market include:
Reata Pharmaceuticals
Takeda Pharmaceuticals
PTC Therapeutics
Cardero Therapeutics
Jupiter Orphan Therapeutics
Retrotope
Voyager Therapeutics
And others.
Friedreich’s Ataxia therapies covered in the report include:
RT001
TAK-831PTC743RTA 408
And many more.
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @
https://www.delveinsight.com/sample-request/friedreichs-ataxia-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Friedreich’s Ataxia Competitive Intelligence Analysis
4. Friedreich’s Ataxia Market Overview at a Glance
5. Friedreich’s Ataxia Disease Background and Overview
6. Friedreich’s Ataxia Patient Journey
7. Friedreich’s Ataxia Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Friedreich’s Ataxia Treatment Algorithm, Current Treatment, and Medical Practices
9. Friedreich’s Ataxia Unmet Needs
10. Key Endpoints of Friedreich’s Ataxia Treatment
11. Friedreich’s Ataxia Marketed Products
12. Friedreich’s Ataxia Emerging Drugs and Latest Therapeutic Advances
13. Friedreich’s Ataxia Seven Major Market Analysis
14. Attribute Analysis
15. Friedreich’s Ataxia Market Outlook (In US, EU5, and Japan)
16. Friedreich’s Ataxia Access and Reimbursement Overview
17. KOL Views on the Friedreich’s Ataxia Market
18. Friedreich’s Ataxia Market Drivers
19. Friedreich’s Ataxia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
Other Trending Healthcare Reports By DelveInsight
Friedreich Ataxia Pipeline Insights
“Friedreich Ataxia Pipeline Insights, 2022” report by DelveInsight outlays comprehensive insights into the present clinical development scenario and growth prospects across Friedreich Ataxia Market.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
